Arrowhead Pharmaceuticals (ARWR) said Monday that it submitted a new drug application to the US Food and Drug Administration for its experimental drug, plozasiran, to treat familial chylomicronemia syndrome, a rare disease that could lead to potentially fatal pancreatitis.
The company said the application is supported by data from a phase 3 study that met primary and key secondary endpoints, including reductions in triglycerides and the incidence of acute pancreatitis.
The drugmaker also said it plans to seek approval for plozasiran from other regulatory authorities in 2025.
Shares of the company were up more than 3% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。